Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gsk Plc ADR (NY: GSK )

35.13 -0.36 (-1.01%)
Official Closing Price Updated: 7:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 5,445,580
Open 35.43
Bid (Size) 34.97 (3)
Ask (Size) 35.48 (20)
Prev. Close 35.49
Today's Range 34.87 - 35.61
52wk Range 28.46 - 46.97
Shares Outstanding 5,385,189,617
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
FDA Approves First Oral Treatment For Anemia Due To Chronic Kidney Disease
 
Via Benzinga
GSK CEO Emma Walmsley On Beating Q4 Earnings
GSK came out with quarterly earnings of $0.64 per share. 
Via Talk Markets

Performance

YTD
-0.45%
-0.45%
1 Month
-0.45%
-0.45%
3 Month
+6.97%
+6.97%
6 Month
-13.47%
-13.47%
1 Year
-23.13%
-23.13%

More News

Read More
Pharma Giants GSK, Novo Nordisk Beat Expectations; But Novartis Dives On A Mixed Report
Via Investor's Business Daily
GSK Posts Higher Q4 Sales, Profits, With Record Sales From Shingles Vaccine
Via Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
Via Benzinga
Preview: GlaxoSmithKline's Earnings
Via Benzinga
Earnings Preview: GSK Q4 Earnings Expected To Decline
Via Talk Markets
GSK Earnings Conference Call Is Coming Up, Here's What You Need To Know
Via Benzinga
Earnings Scheduled For February 1, 2023
Via Benzinga
CureVac Shares Pop After Encouraging Update From COVID-19, Flu mRNA Vaccine Programs
Via Benzinga
The RSV Vaccine Battle Wages On With Moderna Scoring A Win Vs. Pfizer, GSK
Via Investor's Business Daily
How Could GSK's RSV Vaccine Change its Valuation?
Via MarketBeat
Exposures Product Safety
3 Penny Stocks That Could Make You Filthy Rich
Via The Motley Fool
Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering
Via Benzinga
COVID, Shmovid: This Could Be the Next Big Growth Story for Moderna Stock
Via The Motley Fool
Stock Market Rally Pulls Back; Microsoft, Google Slash Jobs; Netflix, Goldman, Tesla In Focus: Weekly Review
Via Investor's Business Daily
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
Via Investor's Business Daily
Jim Cramer Says This Stock Up 23% In A Month Is 'A Great Speculative Buy'
Via Benzinga
Moderna Gets A 'Booster' Shot: Why Stock Is Up Nearly 7% Today
Via Benzinga
Moderna Comes Swinging For Pfizer, GSK As RSV Vaccine Battle Heats Up
Via Investor's Business Daily
Week In Review: WuXi Biologics Out-Licenses Four TCE Antibodies To GSK In $1.5 Billion Pact
Via Talk Markets
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
Via InvestorPlace
The Year of the Tripledemic
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death Product Safety
The Year of the Tripledemic
Via News Direct
Topics Death
Exposures COVID-19 Death
What You Missed On Wall Street On Friday
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.